<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and evaluation of osteoporosis in men</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and evaluation of osteoporosis in men</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and evaluation of osteoporosis in men</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel S Finkelstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine W Yu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is a common disorder that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture. The World Health Organization (WHO) has defined diagnostic thresholds for low bone mass and osteoporosis based upon bone mineral density (BMD) measurements compared with a young adult reference population (T-score)  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>).</p><p>The initial osteoporosis evaluation includes a history to assess for clinical risk factors for fracture and to evaluate for other conditions that contribute to bone loss, a physical examination, and basic laboratory tests. There are many coexisting medical conditions that may contribute to bone loss  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>). Thus, evaluation for alternative causes of bone loss to detect potentially reversible causes should be considered in those with abnormal initial findings.</p><p>Early diagnosis and quantification of bone loss and fracture risk have become more important because of the availability of therapies that can slow or even reverse the progression of osteoporosis.</p><p>The clinical manifestations, diagnosis, and evaluation of osteoporosis in men will be reviewed here. The treatment and the epidemiology and etiology of osteoporosis in men are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">"Etiology of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Osteoporosis has no clinical manifestations until a fracture occurs. Many vertebral fractures are asymptomatic and are discovered as an incidental finding on chest or abdominal radiographs. Asymptomatic vertebral fractures are sentinel events that are strong predictors of future clinically symptomatic fractures. The clinical manifestations of symptomatic vertebral fractures include variable degrees of pain and muscle spasms. The clinical manifestations of vertebral fractures are reviewed in detail separately.</p><p>Hip fractures are the most devastating consequence of osteoporosis in men as they frequently lead to chronic pain, loss of mobility, and increased mortality. Men experience higher mortality than women after sustaining a fragility fracture [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSIS OF OSTEOPOROSIS</span></p><p class="headingAnchor" id="H283621673"><span class="h2">Diagnostic criteria by age</span><span class="headingEndMark"> — </span>Osteoporosis is characterized by low bone mass and microarchitectural disruption, which reduces bone strength and increases the risk of fracture.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>&lt;50 years of age</strong> – In men &lt;50 years of age, bone mineral density (BMD) measurements alone are not sufficient to establish a diagnosis of osteoporosis [<a href="#rid2">2</a>]. Instead, osteoporosis is defined by lower than expected BMD for age (Z-score ≤-2.0) plus a history of a fragility fracture and/or a major risk factor for osteoporosis (eg, hypogonadism, glucocorticoid therapy, hyperparathyroidism)  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>≥50 years of age</strong> – In men ≥50 years, a diagnosis of osteoporosis can be made when there is a history of low trauma (fragility) fracture or in men whose BMD is at least 2.5 standard deviations below the young adult reference mean (ie, T-score of ≤-2.5)  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>). Male and female reference means are variably used across centers to calculate T-scores. (See <a class="local">'Use of a male or female reference database'</a> below.)</p><p></p><p class="headingAnchor" id="H3621773104"><span class="h2">Bone mineral density measurement</span><span class="headingEndMark"> — </span>The use of bone densitometry to diagnose osteoporosis is less well standardized in men than in postmenopausal women [<a href="#rid4">4</a>]. However, because the relationship between BMD and fracture is similar in men age ≥50 years and postmenopausal women, the World Health Organization (WHO) diagnostic thresholds for osteoporosis are similar for both groups  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>). In fact, for every standard deviation that BMD is reduced in men, the relative risk of fracture is similar to, or even greater than, the relative risk in women. However, the age-specific prevalence of osteoporosis and fracture is lower in men than in women, so that men nonetheless tend to have a lower absolute risk for fracture than women [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Dual-energy x-ray absorptiometry (DXA)'</a>.)</p><p class="headingAnchor" id="H373435806"><span class="h2">Controversies in the diagnosis of osteoporosis in men</span></p><p class="headingAnchor" id="H2531292846"><span class="h3">Patient selection for BMD measurement</span><span class="headingEndMark"> — </span>BMD always should be measured in men with a history of fragility fracture(s), height loss of 1.5 inches or more, radiographic osteopenia, or kyphosis, as well as in men with disorders that increase the risk of developing osteoporosis (eg, glucocorticoid use, hypogonadism, malabsorption, primary hyperparathyroidism, rheumatoid arthritis, frailty)  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Candidates for BMD testing'</a>.)</p><p class="headingAnchor" id="H2696572338"><span class="h3">Use of a male or female reference database</span><span class="headingEndMark"> — </span>The decision whether to use a young adult male or female reference database for dual-energy x-ray absorptiometry (DXA) in men is controversial. The ISCD and the WHO both endorse the use of a female reference database to calculate T-scores in men. However, many centers use sex-specific reference databases [<a href="#rid3">3</a>]. With use of sex-specific reference databases, osteoporosis in men is defined by a BMD value at the spine, hip, or forearm at least 2.5 standard deviations below the young, healthy male reference mean. We prefer this approach to diagnose osteoporosis in men because all osteoporosis treatment trials in men recruited participants based on T-scores calculated using healthy male controls [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Reference databases'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Skeletal site selection for BMD measurement</span><span class="headingEndMark"> — </span>We recommend measuring BMD of both the hip and spine. The proximal femur is the best site for evaluating men for osteoporosis. Although lumbar spine BMD is highly useful in the evaluation of osteoporosis in postmenopausal women, men are more likely to have degenerative changes in the lumbar spine, the presence of which increases the measured BMD and limits the utility of spine DXA in men. If pharmacologic therapy is planned, measurement of spine BMD is useful as it shows less inter-measurement variability and can detect responses to therapy earlier than hip BMD.</p><p>If degenerative changes or other factors limit interpretation of BMD measurements of the spine and/or the hip, then some centers routinely measure forearm BMD. Forearm BMD may also be more sensitive than spine or hip DXA for detecting bone loss in men undergoing androgen deprivation therapy for prostate cancer [<a href="#rid6">6</a>].</p><p>Cumulative fracture risk can be predicted by measuring BMD at a variety of sites including the lumbar spine, proximal femur, or the distal radius. Selection of skeletal sites for BMD measurement is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Skeletal site to measure'</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Skeletal site to measure'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The initial evaluation should include history and physical examination, which may provide an explanation for low bone mass (eg, hypogonadism, glucocorticoid excess), routine biochemical tests to uncover renal or hepatic disease, and a complete blood count, serum testosterone, calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D (calcidiol), and 24-hour urine calcium and creatinine  (<a class="graphic graphic_table graphicRef51140" href="/z/d/graphic/51140.html" rel="external">table 3</a>).</p><p>Men who have abnormalities on the initial laboratory testing, have suspicious findings on history and physical examination, or who have unexplained low bone mass after the initial evaluation may also require additional laboratory tests  (<a class="graphic graphic_table graphicRef51140" href="/z/d/graphic/51140.html" rel="external">table 3</a>), such as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parathyroid hormone to screen for primary hyperparathyroidism</strong> – We typically measure this in men with hypercalcemia, hypercalciuria, or history of renal stones. Some clinicians prefer to measure parathyroid hormone in all men with osteoporosis as part of the initial evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estradiol</strong> – In adult men with acquired hypogonadism, estrogen deficiency may contribute more to bone loss than does androgen deficiency, particularly if levels are below 10 to 15 pg/mL [<a href="#rid7">7</a>]. Accurate measurement of such low levels of estradiol is best performed using mass spectroscopy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue transglutaminase antibodies to screen for celiac disease</strong> – We typically measure this in men who have a low 25-hydroxyvitamin D level and/or low urinary calcium. Some experts recommend these tests in all men with idiopathic osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSH</strong> – We measure thyroid-stimulating hormone (TSH) in men who are taking <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>, or if there are clinical findings suspicious for hyperthyroidism (eg, palpitations, heat intolerance, tremor). (See  <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy"</a>.)</p><p></p><p>Additional testing for other, rare conditions associated with osteoporosis should be performed in selected clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum and urine protein electrophoresis to uncover a hematological or myeloproliferative disorder – We typically recommend these measurements in men with anemia and/or vertebral compression fractures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary cortisol excretion – We measure 24-hour urinary free cortisol if clinical manifestations of Cushing syndrome are present. Some experts recommend measurement of 24-hour urine free cortisol in men with unexplained low bone density or vertebral fractures, even in the absence of traditional clinical manifestations of Cushing syndrome. (See  <a class="medical medical_review" href="/z/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Impact of subclinical hypercortisolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase to screen for systemic mastocytosis – We consider performing this measurement in men with fractures, unexplained osteoporosis, or bone pain. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In rare cases, iliac crest bone biopsy after double <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling may be useful, particularly for distinguishing osteoporosis from osteomalacia or in the setting of advanced chronic kidney disease (CKD; stage 4+). The clinical availability of bone biopsy is limited.</p><p></p><p class="headingAnchor" id="H3671194145"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H427616"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83978.html" rel="external">"Patient education: Medicines for osteoporosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Osteoporosis is a silent disorder until a fracture occurs. Complications of fractures include pain, deformity, disability, loss of height, and increased mortality. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of osteoporosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Men aged &lt;50 years</strong> – In men &lt;50 years of age, bone mineral density (BMD) measurements alone are not sufficient to establish a diagnosis of osteoporosis. Instead, osteoporosis is defined by lower than expected BMD for age (Z-score ≤-2.0) plus a history of a fragility fracture and/or a major risk factor for osteoporosis (eg, hypogonadism, glucocorticoid therapy, hyperparathyroidism)  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>). (See <a class="local">'Diagnosis of osteoporosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Men aged ≥50 years</strong> – In men ≥50 years, a diagnosis of osteoporosis can be made when there is a history of low trauma (fragility) fracture or in men whose BMD is at least 2.5 standard deviations below the young adult reference mean (ie, T-score of ≤-2.5)  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis of osteoporosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of men for BMD measurement –</strong> BMD should be measured in men with clinical manifestations of low bone mass, such as radiographic osteopenia, history of low trauma fractures, loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, hypogonadism, primary hyperparathyroidism, intestinal disorders, and increased frailty  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>). Some expert groups recommend BMD measurement in men based on age alone (eg, 70 years or above). (See <a class="local">'Patient selection for BMD measurement'</a> above and  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Candidates for BMD testing'</a>.)</p><p></p><p class="bulletIndent1">We use a male reference database for calculating T-scores in men. (See <a class="local">'Use of a male or female reference database'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The goal of the evaluation of men with osteoporosis is to rule out secondary causes  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 2</a>). Many secondary etiologies of osteoporosis can be determined from history and physical examination. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Most men with low bone mass or fragility fracture should have basic laboratory testing. Initial laboratory studies should include a complete blood count, biochemistry profile, 25-hydroxyvitamin D, testosterone, and measurement of urinary calcium excretion  (<a class="graphic graphic_table graphicRef51140" href="/z/d/graphic/51140.html" rel="external">table 3</a>), particularly if there is no clear explanation for their low BMD. Based on the results of the history, physical examination, and basic laboratory testing, more extensive testing may be indicated. (See <a class="local">'Evaluation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152:380.</a></li><li class="breakAll">ISCD Adult Official Positions (updated in 2019). Available at: https://iscd.org/learn/official-positions/adult-positions/ (Accessed on March 21, 2023).</li><li class="breakAll">2013 ISCD Official Positions - Adult. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/ (Accessed on February 02, 2017).</li><li><a class="nounderline abstract_t">Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am 2007; 36:399.</a></li><li><a class="nounderline abstract_t">Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006; 21:1550.</a></li><li><a class="nounderline abstract_t">Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67:152.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest 2016; 126:1114.</a></li></ol></div><div id="topicVersionRevision">Topic 2052 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231569" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Meta-analysis: excess mortality after hip fracture among older women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231569" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meta-analysis: excess mortality after hip fracture among older women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231569" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Meta-analysis: excess mortality after hip fracture among older women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17543726" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16995809" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413352" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901812" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
